Ann Surg Oncol

1. FLEGAR L, Eisenmenger N, Reimold P, Koch R, et al
   Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis From 2006 to 2022.
   Ann Surg Oncol. 2026;33:8630-8635.
   

   >> Share

   
   

   
   Biomaterials

2. DING Y, Zhu Y, Li J, Chen X, et al
   Mucosa-penetrating NIR-II nanomedicine for precision photoimmunotherapy of bladder cancer.
   Biomaterials. 2026;337:124518.
   

   >> Share

   
   

   
   BJU Int

3. IBRAHIM Y, Ribeiro L, Spazzapan M, Gad M, et al
   Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.
   BJU Int. 2026;138:449-455.
   

   >> Share

   
   
4. CHEN Y, Yue Z
   Incidence is not surveillance yield: interpreting metachronous upper tract urothelial carcinoma risk after non-muscle-invasive bladder cancer.
   BJU Int. 2026 Aug 11. doi: 10.1111/bju.70429.
   

   >> Share

   
   

   
   BMC Cancer

5. TAMBARO R, Calvanese G, Muto A, Formisano L, et al
   Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
   BMC Cancer. 2026;26:956.
   

   >> Share

   
   

   
   BMC Urol

6. OU M, Ji C, Wen J
   A hypervascular perivascular epithelioid cell tumor of the urinary bladder showing TFE3 immunoreactivity clinically misdiagnosed as paraganglioma in an adolescent patient.
   BMC Urol. 2026;26:195.
   

   >> Share

   
   

   
   Cancer Immunol Res

7. GUO Y, Ren X, Zhang Z, Cheng H, et al
   The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.
   Cancer Immunol Res. 2026 Aug 11. doi: 10.1158/2326-6066.CIR-25-1445.
   

   >> Share

   
   

   
   Cancer Res Commun

8. BURGESS EF, Brown L, McCormack M, Liu L, et al
   Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy.
   Cancer Res Commun. 2026 Aug 13. doi: 10.1158/2767-9764.CRC-26-0255.
   

   >> Share

   
   

   
   Cells

9. GOMEZ J, Lakew M, Wilkie H, David B, et al
   Bladder Cancer Cells Maintain Paracrine IL-1 Signaling and IL-1Ra Sensitivity Following Chronic IL-1 Exposure.
   Cells. 2026;15:1376.
   

   >> Share

   
   
10. ZHAO F, Vakhrusheva O, Markowitsch SD, Slade KS, et al
    Correction: Zhao et al. Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins. Cells 2025, 14, 570.
    Cells. 2026;15:1363.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

11. SKUPIN PA, Wu S, Orikogbo O, Chadwick SJ, et al
    Treatment Type and Mortality for Black Versus White Patients With Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jul 17:102626. doi: 10.1016/j.clgc.2026.102626.
    

    >> Share

    
    

    
    Curr Med Chem

12. LI Z, Yan T, Hu C, Lu Z, et al
    Construction and Validation of a Ubiquitination-Related Gene Signature Based on WGCNA and Single-cell RNA Sequencing in Bladder Cancer.
    Curr Med Chem. 2026 Jul 28. doi: 10.2174/0109298673470246260702000813.
    

    >> Share

    
    

    
    Curr Urol Rep

13. SONG L, Meagher M, Saidian A, Salmasi A, et al
    Intravesical Recurrence of Upper Tract Urothelial Carcinoma: Strategies for Prevention.
    Curr Urol Rep. 2026;27:37.
    

    >> Share

    
    

    
    Diagn Pathol

14. GORCZYNSKI A, Tarjan B, Neittaanmaki N
    Deep learning-assisted detection of lymph node metastases in bladder cancer.
    Diagn Pathol. 2026;21:58.
    

    >> Share

    
    

    
    Eur J Cancer

15. PAPADIMITRIOU MA, Pilala KM, Panoutsopoulou K, Soureas K, et al
    Liquid biopsy miRNA risk score in bladder cancer: Translational insights from patient-derived xenografts to prognostic stratification.
    Eur J Cancer. 2026;246:116987.
    

    >> Share

    
    

    
    Eur Urol Focus

16. GABRIEL PE, Zhu A, Karim C, Eraky A, et al
    Prognostic Value of Perioperative Circulating Tumor DNA in Pure Urothelial Carcinoma and Histological Subtypes of Bladder Cancer.
    Eur Urol Focus. 2026 Aug 12:S2405-4569(26)00122.
    

    >> Share

    
    

    
    Eur Urol Oncol

17. SCILIPOTI P, Rosiello G, Salonia A, Briganti A, et al
    Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-412
    Eur Urol Oncol. 2026 Aug 11:S2588-9311(26)00219.
    

    >> Share

    
    

    
    Front Immunol

18. ZHOU Y, Yang X, Tian T, Yang B, et al
    Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer.
    Front Immunol. 2026;17:1896444.
    

    >> Share

    
    

    
    Front Oncol

19. ZHU H, Tan S, Liu X
    Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study.
    Front Oncol. 2026;16:1856699.
    

    >> Share

    
    
20. TIAN J, Li L, Xu L, Liu L, et al
    Effects of self-management interventions on self-care ability and quality of life in patients with urinary ostomy after bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2026;16:1864061.
    

    >> Share

    
    

    
    Healthcare (Basel)

21. PINTON P
    Structural Misalignment Between Regulatory Definitions of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer and Real-World Clinical Practice.
    Healthcare (Basel). 2026;14:2303.
    

    >> Share

    
    

    
    Heliyon

22. NIE W, Jiang Y, Yao L, Zhu X, et al
    Retraction notice to "Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models" [Heliyon 10 (2024) e39327].
    Heliyon. 2025;12:e44476.
    

    >> Share

    
    

    
    Int Immunopharmacol

23. CHEN Y, Wang Z, He C, Yu Z, et al
    KLF6-driven macrophage-to-myofibroblast transition promotes PD-L1-mediated immune evasion in bladder cancer.
    Int Immunopharmacol. 2026;187:117201.
    

    >> Share

    
    
24. LIU J, Hu M, Chen J, Zu X, et al
    Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.
    Int Immunopharmacol. 2026;187:117273.
    

    >> Share

    
    

    
    Int J Mol Sci

25. SUN W, Li Y, Xu M, Guan H, et al
    Oridonin Suppresses Bladder Cancer Growth and Metastasis by Inducing S-Phase Arrest and Apoptosis.
    Int J Mol Sci. 2026;27:6835.
    

    >> Share

    
    
26. AKHMETKALIYEV A, Fritz Garcia JHG, Sonnenberg-Riethmacher E, Riethmacher D, et al
    Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.
    Int J Mol Sci. 2026;27:6807.
    

    >> Share

    
    
27. SANTINI N, Procino A, Ljubic S, Dermic D, et al
    Extracellular Alpha-Satellite DNA in Human Plasma as a Candidate Biomarker for Bladder Cancer Detection: Preliminary Evidence Using Digital PCR.
    Int J Mol Sci. 2026;27:6834.
    

    >> Share

    
    

    
    Int J Urol

28. WATANABE R
    Editorial Comment to "Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study".
    Int J Urol. 2026;33:e70604.
    

    >> Share

    
    

    
    J Clin Med

29. TANG X, Liu J, Zhao Q, Yang X, et al
    The Diagnostic and Prognostic Value of Immunohistochemical Markers in Bladder Cancer: A Real-World Study of 477 Patients.
    J Clin Med. 2026;15:6124.
    

    >> Share

    
    

    
    J Urol

30. GABRIEL PE, Zhu A, Xylinas E, Sfakianos JP, et al
    Beyond the NMIBC-MIBC Dichotomy: Integrating Molecular Biomarkers into Bladder Cancer Risk Stratification.
    J Urol. 2026 Aug 11:101097JU0000000000005255. doi: 10.1097/JU.0000000000005255.
    

    >> Share

    
    

    
    JCO Precis Oncol

31. BEIJERT IJ, Wever BMM, Moldovan N, van den Burgt Y, et al
    Integrated Methylation and Copy Number Analysis for Noninvasive Bladder Cancer Detection in Urine.
    JCO Precis Oncol. 2026;10:e2500882.
    

    >> Share

    
    

    
    Nan Fang Yi Ke Da Xue Xue Bao

32. WU H, Jiang Y, Zhang X, Wang S, et al
    [Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].
    Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1870-1877.
    

    >> Share

    
    

    
    Nat Struct Mol Biol

33. HU Y, Csuka J, Rajbhandari P, Huang P, et al
    PLA2G2F suppresses ferroptosis through phospholipid remodeling.
    Nat Struct Mol Biol. 2026;33:1147-1157.
    

    >> Share

    
    

    
    Oncol Rep

34. ZHU D, Wan X, Huang H, Chen X, et al
    [Corrigendum] Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell?like side population cells.
    Oncol Rep. 2026;56:171.
    

    >> Share

    
    

    
    Pathol Res Pract

35. YANG X, Ding Z, Pengwang Y, Wei Y, et al
    RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF.
    Pathol Res Pract. 2026;286:156625.
    

    >> Share

    
    

    
    Phytomedicine

36. LI F, Chen C, Ye W, Huang Y, et al
    Shikonin inhibits bladder cancer progression by targeting deoxyribonuclease 2 to suppress reticulon 3-dependent endoplasmic reticulum autophagy.
    Phytomedicine. 2026;160:158682.
    

    >> Share

    
    

    
    Technol Cancer Res Treat

37. MAISCH P, Muhlberger M, Beck A, Schreen W, et al
    Evaluation of Stimulated Raman Histology as a Novel Method for Pathologic Examination of Urothelial Carcinoma With Unprocessed, Fresh Bladder Cancer Tissue.
    Technol Cancer Res Treat. 2026;25:15330338261464295.
    

    >> Share

    
    

    
    Transl Androl Urol

38. MIYAKE M
    Rural-urban disparities in high?risk non-muscle?invasive bladder cancer: lessons from the Canadian Bladder Cancer Information System.
    Transl Androl Urol. 2026;15:227.
    

    >> Share

    
    
39. CHEN K, Bai Z, Huang Y
    USP5 silencing inhibits the proliferation of bladder cancer cells and induces cell apoptosis and ferroptosis by destabilizing COL14A1 expression.
    Transl Androl Urol. 2026;15:232.
    

    >> Share

    
    
40. WATANABE H, Ishikawa G, Watanabe S, Watanabe S, et al
    Clinical benefits, tolerability, and risk factors of adjuvant nivolumab for muscle-invasive bladder cancer.
    Transl Androl Urol. 2026;15:234.
    

    >> Share

    
    

    
    Urol Oncol

41. LOTAN Y, Margulis V, Woldu S, Allison D, et al
    Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.
    Urol Oncol. 2026 Aug 10:S1078-1439(26)00601.
    

    >> Share

    
    

    
    World J Urol

42. RASKIN Y, Baekelandt F, Decaestecker K, Seront E, et al
    Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation.
    World J Urol. 2026;44:560.
    

    >> Share

    
    
43. MATSUSHITA Y, Tamura A, Masuda T, Hasegawa O, et al
    Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.
    World J Urol. 2026;44:566.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share